---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-199430"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:45:32.045384+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma Q2 net loss $12.3M; setrusumab studies fully enrolled, fracture rate cut 67%

## Summary
- Cash $87.4M as of June 30, 2024, including $50M June offering; runway into 2027.
- Net loss $12.3M in Q2 2024 vs $1.8M in Q2 2023, driven by $9.0M milestone payment in prior year.
- Phase 3 Orbit and Cosmic studies of setrusumab in OI fully enrolled by April 30, 2024.
- Setrusumab reduced median annualized fracture rate by 67% (p=0.0014) over 16 months mean treatment.
- R&D expenses $4.9M (+33% YoY); G&A expenses $7.9M (+$5.2M) on pre-commercial activity.

## SEC filing metadata
- accession: 0001193125-24-199430
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312524199430/0001193125-24-199430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312524199430/d880557d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-199430
- JSON: https://secwatch.observer/filing/0001193125-24-199430.json
- Plain text: https://secwatch.observer/filing/0001193125-24-199430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.